Prediction and Prevention of Type I Diabetes

I 型糖尿病的预测和预防

• 批准号: 6932444
• 负责人: DOROTHY J BECKER
• 金额: $ 23.21万
• 依托单位: CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-29 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6932444
• 关键词: Internet; T lymphocyte; autoantigens; blood tests; clinical trials; cooperative study; coping; diabetes education; diabetes mellitus therapy; disease /disorder prevention /control; genetic susceptibility; human subject; human therapy evaluation; immunologic assay /test; immunoregulation; immunotherapy; insulin; insulin dependent diabetes mellitus; interview; longitudinal human study; pancreatic islets; patient oriented research; peptides; psychological stressor; statistics /biometry

DESCRIPTION (provided by applicant) This is a submission from the Children?s Hospital and University of Pittsburgh in response to the TrialNet RFA. This group of investigators with extensive experience has formulated four specific aims that answer all the objectives of the TrialNet RFA. Specific Aim 1 extends the current oral arm of DPT-1. Specific Aim 2 proposes the use of T-cell immunology to assess the effectiveness of immune interventions in TrialNet. Specific Aim 3 addresses the important issue of psychosocial and educational needs of subjects screened and included in intervention studies. Specific Aim 4 is a pilot study of a high-affinity peptide with potential safe effectiveness for delaying or preventing progression of autoimmunity. The strength of the application is the expertise and experience of the investigators and well established collaboration across three centers.

描述(由申请人提供) 这是来自匹兹堡大学S儿童医院的投稿 以回应TrialNet RFA。这组调查人员拥有广泛的 经验制定了四个具体目标，回答了以下所有目标 TrialNet RFA。特定目标1扩展了目前DPT-1的口腔手臂。 特定目标2建议使用T细胞免疫学来评估 免疫干预在TrialNet中的有效性。特定目标3解决了 受试者的心理社会和教育需求的重要问题 包括在干预研究中。具体目标4是一项初步研究 具有潜在安全疗效的高亲和力多肽 防止自身免疫的进展。 应用程序的优势在于其专业知识和经验 三个中心的调查人员和良好的合作。